glp-1 drugs and cancer GLP-1s appear to cut risk. Researchers are asking why how : NPR New study examines GLP-1 drugs

In the most directly relevant comparator with semaglutide, MASH resolution was achieved in 62.9% of patients on the drug while fibrosis improvement reached only 36.8%, leaving substantially less overlap than the headline numbers might imply [16]

However, these agents can be expensive for patients whose insurances do not cover the medications

Faster escalation means reaching the effective dose sooner but potentially dealing with more intense gastrointestinal side effects

The Journal of Law and Economics

Upon discovering the impact of systemic GLP-1 on heat sensitivity, we evaluated its influence on the peripheral nervous system through local intraplantar injection of 10 g of GLP-1(736)